Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(145 products)
- Bcr-Abl(102 products)
- EGFR(572 products)
- FAK(72 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(170 products)
- JAK(245 products)
- PDGFR(126 products)
- RAAS(86 products)
- Src(78 products)
- Syk(38 products)
- Thrombin(47 products)
- VDA(2 products)
- VEGFR(268 products)
Show 6 more subcategories
Found 1414 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
FLT3-ITD-IN-3
CAS:<p>FLT3-ITD-IN-3 (13v) is an orally active inhibitor of FLT3-ITD (internal tandem duplication of FLT3), which works by blocking FLT3 signaling. This inhibition leads to cell cycle arrest in the G0/G1 phase and induces apoptosis. The compound is currently employed in studies related to acute myeloid leukemia (AML).</p>Formula:C27H21ClF2N6O5Color and Shape:SolidMolecular weight:582.943AKN-028 acetate
<p>AKN-028 acetate: an oral TK inhibitor for AML research, targets FLT3 with IC50 of 6 nM, inhibits autophosphorylation, and induces apoptosis.</p>Formula:C19H18N6O2Color and Shape:SolidMolecular weight:362.39VEGFR-2-IN-18
<p>VEGFR-2-IN-18 is a potent VEGFR-2 inhibitor with a 60 nM IC50, promoting cell apoptosis and anticancer effects.</p>Formula:C20H13ClN4O2Color and Shape:SolidMolecular weight:376.8CEP-11981
CAS:<p>CEP-11981 is an orally active TIE2/pan-VEGFR inhibitor with broad tyrosine kinase inhibitory activity, antitumour and anti-angiogenic, refractory solid tumours.</p>Formula:C28H27N7OPurity:99.58%Color and Shape:SolidMolecular weight:477.56EGFR-IN-47
<p>EGFR-IN-47: strong oral EGFRL858R/T790M/C797S blocker, induces cell death; promising for NSCLC research. IC50: 0.01 μM.</p>Formula:C29H35N7Color and Shape:SolidMolecular weight:481.64EGFR-IN-58
<p>EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.</p>Formula:C31H30FN7OColor and Shape:SolidMolecular weight:535.61Protein Kinase Inhibitor 12
CAS:<p>Protein Kinase Inhibitor 12 (compound 1-91) is protein kinase inhibitor,PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases.</p>Formula:C14H14N4OSPurity:98.06%Color and Shape:SolidMolecular weight:286.35Tofacitinib Prodrug-1
<p>Tofacitinib Prodrug-1: an oral prodrug reducing Tofacitinib's side effects, treats ulcerative colitis in mice effectively with low toxicity.</p>Formula:C36H39ClN10O7Color and Shape:SolidMolecular weight:759.21Anticancer agent 69
<p>Anticancer agent 69 targets PC3 cells (IC50=26 nM), raises ROS, lowers EGFR, and induces apoptosis.</p>Formula:C19H26N8SColor and Shape:SolidMolecular weight:398.53JAK-2/3-IN-3
<p>JAK-2-/3-IN-3 (ST4j) is a potent JAK2/3 inhibitor for leukemia research, with IC50s: JAK2, 13 nM; JAK3, 14.86 nM; induces apoptosis.</p>Formula:C13H10Cl2N4O2Color and Shape:SolidMolecular weight:325.15HER2-IN-12
<p>HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.</p>Formula:C17H18BrN5O2SColor and Shape:SolidMolecular weight:436.33VEGFR-IN-3
CAS:<p>VEGFR-IN-3 inhibits cancer cell growth (OVCAR-4, MDA-MB-468) with IC50s: 0.29, 0.35μM. Used in cancer research.</p>Formula:C27H28N2O6Color and Shape:SolidMolecular weight:476.52JAK2/FLT3-IN-1 TFA
<p>JAK2/FLT3-IN-1 (TFA), an oral JAK2/FLT3 inhibitor, shows anticancer properties; IC50: JAK2 (0.7 nM), FLT3 (4 nM), JAK1 (26 nM), JAK3 (39 nM).</p>Formula:C27H35F4N7O3Color and Shape:SolidMolecular weight:581.61DHFR-IN-4
CAS:<p>DHFR-IN-4 is a potent dihydrofolate reductase (DHFR) inhibitor with anti-tumour activity, inhibits EGFR and HER2 and can be used to study pancreatic cancer.</p>Formula:C18H21N5O2SPurity:99.41%Color and Shape:SolidMolecular weight:371.46EGFR-IN-125
CAS:<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Formula:C30H26N8OColor and Shape:SolidMolecular weight:514.58JAK3-IN-11
CAS:<p>JAK3-IN-11: potent oral JAK3 inhibitor (IC50=1.7 nM), noncytotoxic, >588-fold selectivity, blocks T-cell growth; useful in autoimmune research.</p>Formula:C23H23N5O2Color and Shape:SolidMolecular weight:401.46EGFR/HER2-IN-7
<p>EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.</p>Formula:C19H21N3O2SColor and Shape:SolidMolecular weight:355.45HDAC-IN-35
<p>HDAC-IN-35 (Compound 14) is an effective and selective inhibitor of VEGFR-2 and HDAC, with IC50 values of 13.2 and 0.166 μM for VEGFR-2 and HDAC6, respectively.</p>Formula:C17H13ClF3N3O3Color and Shape:SolidMolecular weight:399.75NDI-034858
CAS:<p>NDI-034858 (TAK-279) is a tyrosine kinase 2 (TYK2) inhibitor (Kd<200 pM) that targets the JH2 structural domain of Tyk2 for the treatment of autoimmune diseases</p>Formula:C23H24N8O3Purity:>99.99%Color and Shape:SolidMolecular weight:460.49JAK2-IN-7
CAS:<p>JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.</p>Formula:C26H33N7OPurity:99.54%Color and Shape:SolidMolecular weight:459.59
